Pharma BD Deal Intelligence
Roche acquired the remaining shares of Foundation Medicine for $137 per share to accelerate broad availability of comprehensive genomic profiling in oncology…
Tender offer expired 12:00 midnight ET end of July 30, 2018; Roche accepted all validly tendered shares at $137.00/share. Following the second-step merger, FMI…
Roche's subsidiary accepted for payment all shares validly tendered and not validly withdrawn in its tender offer for Foundation Medicine at $137.00 per share;…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Roche acquired the remaining ~43% of Foundation Medicine it did not already own for approximately $2.4 billion ($137 per share), implying a total equity value of ~$5.3 billion. The deal gave Roche full control of FMI's comprehensive genomic profiling platform, FoundationOne CDx, to pair diagnostics with its oncology therapeutics.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Foundation Medicine, Inc. (this deal) | 2018 | $5.3B | 85 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / GlycArt Biotechnology AG | 2005 | $182M | 80 |
← Browse all deals · How we score deals
More: 2018 deals · Roche Holding AG deals · Oncology deals